3 completed, 3 not yet recruiting, 2 recruiting, 1 active not recruiting. 5 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Pyrazinamide (Z): new trials by email Literature Review of Pyrazinamide (Z) trials Research Report on Pyrazinamide (Z)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2026-10-01 | 2026-09-29 |
| Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB) | Phase 3 | Not yet recruiting | University College, London | 784 | 2025-11-01 | 2025-09-09 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| PK Study of Anti-TB Drugs Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis | Phase 1 | Completed | University of Oxford | 61 | 2015-07-07 | 2018-10-03 |
| Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) TMC207 (J), PA-824 (PA), pyrazinamide (Z) - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 105 | 2012-10-01 | 2016-12-13 |
| Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) Moxifloxacin (M), Pretomid (Pa), Pyrazinamide (Z) - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 207 | 2012-03-01 | 2018-06-28 |
Tuberculosis (6) · Tuberculosis, Pulmonary (6)
Global Alliance for TB Drug Development (3) · Shenzhen Third People's Hospital (2) · University College, London (2) · University of Oxford (1) · University of Wisconsin, Madison (1)
South Africa (5) · Tanzania (3) · Uganda (2) · China (1) · Georgia (1) · Moldova (1) · Pakistan (1) · Peru (1) · Philippines (1) · Thailand (1) · Vietnam (1) · Zimbabwe (1)
Andreas Diacon, MD (1) · Anthony Garcia-Prats, MD, MSc, PhD (1) · Morounfolu Olugbosi, MD (1) · Rodney Dawson, MD (1)
PMID 36808186, PMID 25622149, PMID 25795076, PMID 26038418, PMID 26104205, PMID 36053506, PMID 36546625, PMID 37567554, PMID 37980911, PMID 39651910, PMID 41616265, PMID 42156227
U01AI192041 (1)